CA19-9 decrease at 8 weeks as a predictor of overall survival (OS) in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients with metastatic pancreatic cancer (MPC).

被引：0

作者：

Chiorean, E. Gabriela

Von Hoff, Daniel D.

Ervin, Thomas J.

Arena, Francis P.

Infante, Jeffrey R.

Bathini, Venu Gopal

Wood, Tina Evans

Mainwaring, Paul N.

Muldoon, Robert T.

Clingan, Philip R.

Kunzmann, Volker

Ramanathan, Ramesh K.

Tabernero, Josep

Goldstein, David

Ko, Amy

Lu, Brian

机构：

[1] Univ Washington, Seattle, WA 98195 USA

[2] Scottsdale Healthcare TGen, Virginia G Piper Canc Ctr Clin Trials, Scottsdale, AZ USA

[3] Florida Canc Specialists, Englewood, FL USA

[4] Arena Oncol Associates, Lake Success, NY USA

[5] Sarah Cannon Res Inst, Nashville, TN USA

[6] Tennessee Oncol, Nashville, TN USA

[7] Univ Massachusetts, Sch Med, Canc Ctr Excellence, Worcester, MA USA

[8] UAB Comprehens Canc Ctr, Birmingham, AL USA

[9] Mater Private Ctr Haematol & Oncol, South Brisbane, Australia

[10] Genesis Canc Ctr, Hot Springs, AR USA

[11] Southern Med Day Care Ctr, Wollongong, NSW, Australia

[12] Univ Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany

[13] Vall dHebron Univ Hosp, Barcelona, Spain

[14] Prince Wales Hosp, Sydney, NSW, Australia

[15] Celgene Corp, Summit, NJ USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4058

引用

页数：1

共 50 条

[21] Outcomes from the Asian region of the phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for patients (pts) with resected pancreatic cancer (PC)
Park, J. Oh
Li, C-P.
Chang, H-M.
Shan, Y. S.
Bendell, J.
Garlipp, B.
Hatoum, H.
Laquente Saez, B.
Salminen, T.
Oettle, H.
Kocsis, J.
Lopez, R.
Dowden, S.
Karthaus, M.
Lu, B.
McGovern, D.
Banerjee, S.
Tempero, M.
Oh, D-Y.
ANNALS OF ONCOLOGY, 2020, 31 : S1313 - S1313
[22] A phase II study of Chinese patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) for metastatic pancreatic cancer (MPC)
Shen, Lin
Yu, Xianjun
Hao, Jihui
Wang, Liwei
Pan, Hongming
Han, Guohong
Xu, Jian-Ming
Zhang, Yanqiao
Yang, Shujun
Chen, Jia
Ying, Jieer
Dai, Guanghai
Li, Mingyu
Begic, Damir
Lu, Brian D.
Xu, Ruihua
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
[23] APACT: A Phase III Trial of Nab-Paclitaxel (nab-P) Plus Gemcitabine (Gem) Versus Gem Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (PC)
Tempero, Margaret
Cardin, Dana
Biankin, Andrew
Goldstein, David
Moore, Malcolm
O'Reilly, Eileen
Philip, Philip
Riess, Hanno
Macarulla, Teresa
Yung, Lotus
Wei, Xinyu
Lu, Brian
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S72 - S72
[24] APACT: Phase III, Multicenter, International, Open-Label, Randomized Trial of Adjuvant nab-Paclitaxel Plus Gemcitabine (nab-P/G) Versus Gemcitabine (G) for Surgically Resected Pancreatic Adenocarcinoma
Ko, A.
Reni, M.
Riess, H.
Pelzer, U.
O'Reilly, E. M.
Winter, J.
Oh, D. Y.
Li, C. P.
Tortora, G.
Chang, H. M.
Lopez, C. D.
Tabernero, J.
Van Cutsem, E.
Philip, P.
Goldstein, D.
Berlin, J. D.
Ferrara, S.
Li, M.
Lu, B.
Romano, A.
Marks, H.
Biankin, A.
Tempero, M. A.
PANCREAS, 2019, 48 (10) : 1464 - 1464
[25] APACT: Phase III randomized trial of adjuvant treatment with nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with resected pancreatic cancer (PC).
Tempero, Margaret A.
Cardin, Dana Backlund
Goldstein, David
O'Reilly, Eileen Mary
Philip, Agop Philip
Riess, Hanno
Macarulla, Teresa
Yung, Lotus
Li, Mingyu
Lu, Brian D.
Biankin, Andrew
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
[26] Analyses of updated overall survival (OS) and prognostic effect of neutrophil-to-lymphocyte ratio (NLR) and CA 19-9 from the phase III MPACT study of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem for patients (pts) with metastatic pancreatic cancer (PC).
Goldstein, David
EI-Maraghi, Robert Hassan
Hammel, Pascal
Heinemann, Volker
Kunzmann, Volker
Sastre, Javier
Scheithauer, Werner
Siena, Salvatore
Macarulla, Teresa
Teixeira, Luis
Tortora, Giampaolo
Van Laethem, Jean Luc
Penenberg, Darryl Neil
Lu, Brian
Romano, Alfredo
Von Hoff, Daniel D.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[27] SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study
Von Hoff, D. D.
Ramanathan, R.
Borad, M.
Laheru, D.
Smith, L.
Wood, T.
Korn, R.
Desai, N.
Iglesias, J.
Hidalgo, M.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[28] International phase II trial of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) in patients with locally advanced pancreatic cancer (LAPC): LAPACT
Philip, P.
Kayitalire, L.
Nydam, T.
Penenberg, D.
Hammel, P.
ANNALS OF ONCOLOGY, 2015, 26
[29] Phase 1 study of nivolumab (nivo) plus nab-paclitaxel (nab-P) ± gemcitabine (G) in pancreatic cancer (PC): safety evaluation of patients treated with nivo plus nab-P in arm A
Hochster, Howard S.
Wainberg, Zev A.
Gutierrez, Martin
Waterhouse, David
Chiorean, E. Gabriela
George, Ben
Ko, Amy
Manax, Victoria
Stergiopoulos, Sotirios
O'Dwyer, Peter
CANCER RESEARCH, 2016, 76
[30] Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial
Scheithauer, Werner
Ramanathan, Ramesh K.
Moore, Malcolm
Macarulla, Teresa
Goldstein, David
Hammel, Pascal
Kunzmann, Volker
Liu, Helen
McGovern, Desmond
Romano, Alfredo
Von Hoff, Daniel D.
JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2016, 7 (03) : 469 - +

← 1 2 3 4 5 →